imatinib mesylate has been researched along with Canine Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandre, PA; Brandão, PE; Casagrande, TAC; Dagli, MLZ; de Queiroz, GF; Fukumasu, H; Macedo, TR; Matera, JM; Melo, SR; Pinto, ACBCF | 1 |
| Ferro, S; Giantin, M; Romanelli, G; Treggiari, E | 1 |
| Chen, W; Cheng, C; Lee, J; Liao, AT; Lin, C; Liu, B; Liu, C; Liu, I; Tomiyasu, H | 1 |
| Amagai, Y; Ishizaka, S; Jang, H; Jung, K; Matsuda, A; Matsuda, H; Nishikawa, S; Oida, K; Tanaka, A | 1 |
| Bonkobara, M; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Sawada, H; Washizu, T; Yasuda, A | 1 |
| Arita, N; Arita, S; Hikasa, Y | 1 |
| Fukazawa, E; Kobayashi, T; Nakano, Y; Oshima, F; Shiraishi, Y; Takanosu, M; Yamagami, T | 1 |
| Ha, J; Jang, HM; Jung, DI; Jung, HW; Kim, JH; Lee, HC; Moon, JH; Sur, JH | 1 |
| Bonkobara, M | 1 |
| Irie, M; Kagawa, Y; Miyoshi, T; Nagata, N; Ohtake, Y; Suzuki, H; Takeuchi, Y; Yamagami, T | 1 |
| Bracha, S; Goodall, CP; Helfand, SC; Löhr, CV; Marley, K; Milovancev, M | 1 |
| Blazejczyk, A; Dziegiel, P; Dzimira, S; Hildebrand, W; Krupa, A; Kutkowska, J; Obminska-Mrukowicz, B; Pawlak, A; Rapak, A; Strzadala, L; Wietrzyk, J; Ziolo, E | 1 |
| Kawarai, S; Masuda, K; Matsuda, H; Nishimura, R; Ohmori, K; Sasaki, N; Tanaka, A; Tsujimoto, H; Yasuda, N | 1 |
| Al-Sarraf, R; Johnson, CS; Malone, EK; Rassnick, KM; Ruslander, DM; Russell, DS; Trump, DL; Wakshlag, JJ | 1 |
| Bonkobara, M; Ishii, N; Isotani, M; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Sasaki, Y; Sugisaki, O; Washizu, T; Yamada, O | 1 |
| Bonkobara, M; Ishii, N; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Sasaki, Y; Sugisaki, O; Washizu, T; Yamada, O | 1 |
| Bertani, C; Magi, GE; Mari, S; Marini, C; Ogilvie, G; Renzoni, G; Rossi, G | 1 |
| Hioki, K; Kawabata, M; Kobie, K; Maruo, K; Matsuda, H; Mori, T; Tanaka, A | 1 |
1 review(s) available for imatinib mesylate and Canine Diseases
| Article | Year |
|---|---|
Dysregulation of tyrosine kinases and use of imatinib in small animal practice.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Imatinib Mesylate; Neoplasms; src-Family Kinases | 2015 |
2 trial(s) available for imatinib mesylate and Canine Diseases
| Article | Year |
|---|---|
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine | 2010 |
The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Imatinib Mesylate; Mast-Cell Sarcoma; Mice; Mice, SCID; Piperazines; Pyrimidines; Skin Neoplasms; Specific Pathogen-Free Organisms; Statistics, Nonparametric; Xenograft Model Antitumor Assays | 2007 |
15 other study(ies) available for imatinib mesylate and Canine Diseases
| Article | Year |
|---|---|
Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.
Topics: Animals; Dog Diseases; Dogs; Imatinib Mesylate; Myeloproliferative Disorders; Prednisone; Vinblastine | 2022 |
Canine gastrointestinal stromal tumours treated with surgery and imatinib mesylate: three cases (2018-2020).
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit | 2023 |
Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Imatinib Mesylate; Lymphoma, B-Cell; Protein Kinase Inhibitors | 2019 |
Increased expression of the antiapoptotic protein MCL1 in canine mast cell tumors.
Topics: Animals; Benzamides; Chromones; Dog Diseases; Dogs; Electrophoresis, Polyacrylamide Gel; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; Imatinib Mesylate; Janus Kinases; Mastocytoma; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Pyrimidines; Sirolimus; Tyrphostins | 2013 |
Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzamides; Dog Diseases; Dogs; Exons; Female; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Deletion | 2013 |
Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Topics: Animals; Benzamides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Hypertension, Pulmonary; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
Topics: Animals; Base Sequence; Benzamides; Dog Diseases; Dogs; Female; Gene Components; Imatinib Mesylate; Lymphatic Metastasis; Male; Mastocytosis; Molecular Sequence Data; Mutation, Missense; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion; Treatment Outcome | 2014 |
Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog.
Topics: Animals; Benzamides; Cerebellar Neoplasms; Dog Diseases; Dogs; Fatal Outcome; Hydroxyurea; Imatinib Mesylate; Male; Meningioma; Piperazines; Prednisolone; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
Topics: Animals; Antineoplastic Agents; DNA, Complementary; Dog Diseases; Dogs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation; Imatinib Mesylate; Mutation; Proto-Oncogene Proteins c-kit | 2015 |
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Doxorubicin; Fibrosarcoma; Imatinib Mesylate; Mouth Neoplasms; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Celecoxib; Cell Line, Tumor; Dexamethasone; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Imatinib Mesylate; Leukemia, B-Cell; Mice; Neoplasm Transplantation; Piroxicam | 2017 |
Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Topics: Animals; Base Sequence; Benzamides; Cell Line; Cell Proliferation; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Male; Mast Cells; Mastocytoma; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Imatinib Mesylate; Male; Mastocytoma, Skin; Phosphorylation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2011 |
Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Female; Imatinib Mesylate; Intestinal Neoplasms; Mastocytosis, Systemic; Phosphorylation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2012 |
Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Biopsy; Caspase 3; Dog Diseases; Dogs; Exons; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Male; Mast Cells; Mastocytoma, Skin; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |